Lineage Cell Therapeutics (LCTX) Gross Profit (2011 - 2026)

Lineage Cell Therapeutics' Gross Profit history runs 16 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• On a quarterly basis, Gross Profit rose 17.67% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $14.7 million, a 57.99% increase from a year earlier, with the FY2025 full-year figure at $14.4 million, up 57.23% from the prior year.
• Gross Profit declined to $1.7 million in Q1 2026 per LCTX's latest filing, from $6.5 million in the prior quarter.
• Across five years, Gross Profit topped out at $6.5 million in Q4 2025 and bottomed at $1.1 million in Q3 2023.
• The 5-year median for Gross Profit is $2.7 million (2024), against an average of $2.8 million.
• Across the five-year window, Gross Profit surged 1713.98% in 2022 and sank 61.02% in 2023, its largest moves.
• Year by year, Gross Profit stood at $1.8 million in 2022, then advanced by 1.05% to $1.8 million in 2023, then surged by 48.14% to $2.7 million in 2024, then surged by 141.05% to $6.5 million in 2025, then tumbled by 73.63% to $1.7 million in 2026.
• Per Business Quant, the three latest LCTX Gross Profit figures stand at $1.7 million (Q1 2026), $6.5 million (Q4 2025), and $3.7 million (Q3 2025).